Alpha Tau Medical Data Published in Cancers Journal

Ticker: DRTSW · Form: 6-K · Filed: Jun 25, 2024 · CIK: 1871321

Alpha Tau Medical Ltd. 6-K Filing Summary
FieldDetail
CompanyAlpha Tau Medical Ltd. (DRTSW)
Form Type6-K
Filed DateJun 25, 2024
Risk Levelmedium
Pages1
Reading Time1 min
Sentimentbullish

Sentiment: bullish

Topics: medical-technology, clinical-data, publication

TL;DR

Alpha Tau's long-term cancer treatment data just got published in Cancers journal. Looks good.

AI Summary

Alpha Tau Medical Ltd. announced on June 25, 2024, the publication of long-term safety and efficacy data for its superficial cancer treatment in the journal Cancers. The data covers multiple hard-to-treat superficial cancers, demonstrating the continued potential of their technology.

Why It Matters

Positive long-term data publication in a peer-reviewed journal can enhance investor confidence and potentially attract new clinical partners or patients for Alpha Tau's cancer treatment.

Risk Assessment

Risk Level: medium — While positive data is encouraging, the actual market impact and adoption of the technology remain subject to further clinical trials, regulatory approvals, and commercialization success.

Key Players & Entities

  • Alpha Tau Medical Ltd. (company) — Registrant and subject of the press release
  • Cancers (company) — Journal where data was published
  • June 25, 2024 (date) — Date of the press release

FAQ

What specific hard-to-treat superficial cancers were included in the study?

The filing states the data covers 'multiple hard-to-treat superficial cancers' but does not specify which ones in the provided text.

What is the "long-term" duration of the safety and efficacy data presented?

The filing mentions 'long-term' data but does not specify the exact time period covered by the study in the provided text.

Is this publication a part of a specific clinical trial phase?

The filing does not specify which clinical trial phase this publication relates to, only that it presents safety and efficacy data.

What is the significance of being published in the journal 'Cancers'?

Publication in a peer-reviewed journal like 'Cancers' suggests that the data has undergone scientific scrutiny and is considered credible by the medical community.

Does this 6-K filing include the full press release or just a summary?

The filing states that a copy of the press release is attached as Exhibit 99.1, indicating the full release is included.

Filing Stats: 307 words · 1 min read · ~1 pages · Grade level 11 · Accepted 2024-06-25 08:32:36

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Alpha Tau Medical Ltd. Date: June 25, 2024 By: /s/ Uzi Sofer Uzi Sofer Chief Executive Officer 3

View Full Filing

View this 6-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.